A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Laruparetigene zovaparvovec (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- Acronyms Skyline
- Sponsors Beacon Pharmaceuticals
- 12 Jun 2024 According to Beacon Therapeutics media release, the company plans to use the data generated from the VISTA trial, in combination with data from the Phase 1/2 HORIZON and Phase 2 SKYLINE studies, including all available long-term data, to support a BLA in the US and a MAA in Europe for the treatment of patients with XLRP.
- 08 Feb 2024 According to Beacon Therapeutics media release, 12-month interim safety and efficacy results for the Phase 2 SKYLINE trial in patients with X-linked retinitis pigmentosa (XLRP) presented at the 47th Annual Macula Society Meeting in Palm Springs, California.
- 08 Feb 2024 Results published in the Media Release